Difference between revisions of "Etoposide (Vepesid)"
Jump to navigation
Jump to search
m (→References) |
m |
||
| Line 10: | Line 10: | ||
*[[Acute myeloid leukemia]] | *[[Acute myeloid leukemia]] | ||
*[[Acute promyelocytic leukemia]] | *[[Acute promyelocytic leukemia]] | ||
| − | |||
*[[Adult T-cell leukemia-lymphoma]] | *[[Adult T-cell leukemia-lymphoma]] | ||
*[[Anaplastic large cell lymphoma]] | *[[Anaplastic large cell lymphoma]] | ||
| − | *[[ | + | *[[B-cell acute lymphoblastic leukemia]] |
*[[Burkitt lymphoma]] | *[[Burkitt lymphoma]] | ||
*[[Central nervous system (CNS) cancer]] | *[[Central nervous system (CNS) cancer]] | ||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
| + | *[[Ewing's sarcoma]] | ||
*[[Extranodal NK/T-cell lymphoma, nasal type]] | *[[Extranodal NK/T-cell lymphoma, nasal type]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
*[[Hemophagocytic lymphohistiocytosis]] | *[[Hemophagocytic lymphohistiocytosis]] | ||
*[[Hepatobiliary cancer]] | *[[Hepatobiliary cancer]] | ||
| + | *[[Histiocytoses]] | ||
*[[HIV-associated lymphoma]] | *[[HIV-associated lymphoma]] | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
| Line 31: | Line 32: | ||
*[[NK/T-cell lymphoma]] | *[[NK/T-cell lymphoma]] | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
| + | *[[Osteosarcoma]] | ||
*[[Ovarian cancer]] | *[[Ovarian cancer]] | ||
*[[Peripheral T-cell lymphoma]] | *[[Peripheral T-cell lymphoma]] | ||
| Line 159: | Line 161: | ||
[[Category:Topoisomerase inhibitors]] | [[Category:Topoisomerase inhibitors]] | ||
| − | |||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:Acute promyelocytic leukemia medications]] | [[Category:Acute promyelocytic leukemia medications]] | ||
[[Category:Adult T-cell leukemia-lymphoma medications]] | [[Category:Adult T-cell leukemia-lymphoma medications]] | ||
[[Category:Anaplastic large cell lymphoma medications]] | [[Category:Anaplastic large cell lymphoma medications]] | ||
| − | [[Category: | + | [[Category:B-cell acute lymphoblastic leukemia medications]] |
[[Category:Burkitt lymphoma medications]] | [[Category:Burkitt lymphoma medications]] | ||
[[Category:Cancer of unknown primary medications]] | [[Category:Cancer of unknown primary medications]] | ||
| Line 170: | Line 171: | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
| + | [[Category:Ewing's sarcoma medications]] | ||
[[Category:Extranodal NK/T-cell lymphoma, nasal type medications]] | [[Category:Extranodal NK/T-cell lymphoma, nasal type medications]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
[[Category:Hemophagocytic lymphohistiocytosis medications]] | [[Category:Hemophagocytic lymphohistiocytosis medications]] | ||
[[Category:Hepatobiliary cancer medications]] | [[Category:Hepatobiliary cancer medications]] | ||
| + | [[Category:Histiocytoses medications]] | ||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
| Line 183: | Line 186: | ||
[[Category:NK/T-cell lymphoma medications]] | [[Category:NK/T-cell lymphoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Osteosarcoma medications]] | ||
[[Category:Ovarian cancer medications]] | [[Category:Ovarian cancer medications]] | ||
| + | [[Category:Peripheral T-cell lymphoma medications]] | ||
[[Category:Primary mediastinal B-cell lymphoma medications]] | [[Category:Primary mediastinal B-cell lymphoma medications]] | ||
[[Category:Sarcoma medications]] | [[Category:Sarcoma medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
| − | |||
[[Category:Testicular cancer medications]] | [[Category:Testicular cancer medications]] | ||
[[Category:Thymoma medications]] | [[Category:Thymoma medications]] | ||
| + | [[Category:Transformed lymphoma medications]] | ||
[[Category:Transplant medications]] | [[Category:Transplant medications]] | ||
[[Category:Drugs FDA approved in 1983]] | [[Category:Drugs FDA approved in 1983]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 17:23, 21 July 2017
General information
Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Adult T-cell leukemia-lymphoma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Burkitt lymphoma
- Central nervous system (CNS) cancer
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Ewing's sarcoma
- Extranodal NK/T-cell lymphoma, nasal type
- Follicular lymphoma
- Hemophagocytic lymphohistiocytosis
- Hepatobiliary cancer
- Histiocytoses
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Mantle cell lymphoma
- Mediastinal gray-zone lymphoma
- Multiple myeloma
- Neuroendocrine tumors
- NK/T-cell lymphoma
- Non-small cell lung cancer
- Osteosarcoma
- Ovarian cancer
- Peripheral T-cell lymphoma
- Primary mediastinal B-cell lymphoma
- Sarcoma
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Transformed lymphoma
- Transplant conditioning regimens
- Unknown primary
Patient drug information
- Etoposide (Vepesid) patient drug information (Chemocare)[3]
- Etoposide (Vepesid) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 11/10/1983: Initial FDA approval for refractory testicular tumors
Also known as
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Abic Etoposide | Aside | Beposid | Bioposide | BO RUI | Bristol VP-16 | Celltop | Citodox |
| Epocin | Eposid | Eposide | Eposido | Eposin | Epsidox | ETO | Etocris |
| Etomedac | Etonolver | Etopofos | Etopophos | Etopos | Etoposid | Etoposide Abic | Etoposid Ebewe |
| Etoposide Bigmar | Etoposide BVI | Etoposide Dakota | Etoposide DBL | Etoposide DUP | Etoposide Ebewe | Etoposide Eurocept | Etoposide Merck |
| Etoposide Pfizer | etoposide phosphate | Etoposide Teva | Etoposid Mayne | Etoposido | Etoposido Delta Farma | Etoposido Ferrer | Etoposido GI Kendr |
| Etoposido Servycal | Etoposido Varifarm | Etoposid Proreo | Etoposid Teva | Etopoxan | Etopul | Etosid | Etosin |
| Eunades CS | Euvaxon | Exitop | Fytop | Fytosid | HAI WEI LIN | Labimion | Lastet |
| Lastet S | Neoplaxol | Nexvep | Onkoposid | Optasid | P&U Etoposide | Percas | Posid |
| Posidon | Posyd | Riboposid | Sintopozid | Toposar | Toposide | Toposin | Topresid |
| Tosuben | Vepefos | Vepeside | Vepesid K | Vepesid S | Vepesid VP-16 | Vepsid | Vepside |
| VP-16 | VP-TEC | VP 16213 | |||||
References
Categories:
- Drug index
- Chemotherapy
- Intravenous chemotherapy
- Oral chemotherapy
- Irritant chemotherapy
- Topoisomerase inhibitors
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Adult T-cell leukemia-lymphoma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Burkitt lymphoma medications
- Cancer of unknown primary medications
- Central nervous system (CNS) cancer medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Ewing's sarcoma medications
- Extranodal NK/T-cell lymphoma, nasal type medications
- Follicular lymphoma medications
- Hemophagocytic lymphohistiocytosis medications
- Hepatobiliary cancer medications
- Histiocytoses medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Mantle cell lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Multiple myeloma medications
- Neuroendocrine tumor medications
- NK/T-cell lymphoma medications
- Non-small cell lung cancer medications
- Osteosarcoma medications
- Ovarian cancer medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- Sarcoma medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Transformed lymphoma medications
- Transplant medications
- Drugs FDA approved in 1983
- WHO Essential Cancer Medicine